Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2547)	6/17/2010 10:28:38 AM
From: Jibacoa	Respond to of 3722

ONTY opened with a good UG and was up 23.93% but is up only 14.15% at present.<g> Volume is already 2x its ADV bigcharts.marketwatch.com It announced today that MRKGaA and its U.S. affiliate, EMD Serono, are resuming the worldwide development program for Stimuvax (BLP25 liposomal vaccine) for NSCLC. The treatment and enrollment in the PIIIs START and INSPIRE studies will restart after approval by the local regulatory authorities and ethics committees. The FDA has partially lifted the hold it placed on the IND application for BLP25 liposome vaccine in March and will allow the START trial to be resumed. The PIII STRIDE in advanced breast Ca. remains on clinical hold by the FDA and Merck Serono will continue to work closely with the FDA to decide the next steps for this trial. The clinical hold followed a suspected unexpected serious adverse reaction of encephalitis, observed in a patient enrolled in an exploratory PII of BLP25 liposome vaccine in patients with M.M. The protocols in the NSCLC trials are being amended to add specific safety measures.<g> The ACTAY is $5.20 And as previously mentioned, with some good news ONTY has plenty of room to run.<g> bigcharts.marketwatch.com Bernard